MIV 818

Drug Profile

MIV 818

Alternative Names: MIV-818

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Medivir AB
  • Class Antineoplastics
  • Mechanism of Action Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 05 Apr 2017 Pharmacodynamics and pharmacokinetic results from a preclinical study in Hepatocellular carcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Nov 2016 Preclinical trials in Hepatocellular carcinoma in Sweden (PO)
  • 30 Jun 2015 Early research in Hepatocellular carcinoma in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top